Analysts Issue Forecasts for Aethlon Medical Q2 Earnings

Aethlon Medical, Inc. (NASDAQ:AEMD) – Investment analysts at Zacks Small Cap lifted their Q2 2026 earnings estimates for shares of Aethlon Medical in a note issued to investors on Tuesday, October 21st. Zacks Small Cap analyst M. Marin now forecasts that the medical equipment provider will earn ($2.39) per share for the quarter, up from their prior forecast of ($7.00). The consensus estimate for Aethlon Medical’s current full-year earnings is ($0.73) per share. Zacks Small Cap also issued estimates for Aethlon Medical’s Q3 2026 earnings at ($2.46) EPS and Q4 2026 earnings at ($2.78) EPS.

Other equities research analysts have also issued research reports about the stock. HC Wainwright restated a “neutral” rating on shares of Aethlon Medical in a report on Thursday, August 14th. Weiss Ratings restated a “sell (e+)” rating on shares of Aethlon Medical in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Aethlon Medical to a “sell” rating in a report on Saturday, August 30th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus target price of $560.00.

Aethlon Medical Price Performance

AEMD opened at $4.85 on Thursday. Aethlon Medical has a fifty-two week low of $4.65 and a fifty-two week high of $84.40. The firm has a market capitalization of $1.26 million, a PE ratio of -0.38 and a beta of 1.82. The company’s 50-day moving average is $9.53 and its 200 day moving average is $17.64.

Aethlon Medical (NASDAQ:AEMD) last posted its earnings results on Wednesday, August 13th. The medical equipment provider reported ($8.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($6.80) by ($1.70).

Institutional Investors Weigh In On Aethlon Medical

A hedge fund recently bought a new stake in Aethlon Medical stock. Armistice Capital LLC acquired a new stake in Aethlon Medical, Inc. (NASDAQ:AEMD) in the 1st quarter, according to the company in its most recent filing with the SEC. The firm acquired 1,427,946 shares of the medical equipment provider’s stock, valued at approximately $511,000. Armistice Capital LLC owned about 8.89% of Aethlon Medical as of its most recent filing with the SEC. Institutional investors own 1.99% of the company’s stock.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.